[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"developmental-disabilities\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:developmental-disabilities":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,88,124,158],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100638722","act-dad-interview-act-for-fathers-of-children-with-special-needs-100638722",false,"NCT07591636","ACT Dad Interview: ACT for Fathers of Children With Special Needs","A Qualitative Study to Develop a Protocol Using Acceptance and Commitment Therapy (ACT) for Fathers of Children With Special Needs in Improving Their Psychological Flexibility and Mental Health","Informants will include 2 groups, 1) fathers rearing children with special needs and 2) social workers.\n\nFor fathers,\n\nInclusion Criteria:\n\n1. are the biological fathers of children aged 2 to 12 years,\n2. are with a child having a formal diagnosis of a developmental disability, including autism spectrum disorder, attention deficit\u002Fhyperactivity disorder, intellectual disability, or related neurodevelopmental conditions,\n3. are able to speak Cantonese and read Chinese.\n\nExclusion Criteria:\n\n1. Fathers with physical or cognitive impairment\n2. Father with learning problems as identified from NGO or related medical records\n\nFor social workers,\n\nInclusion Criteria:\n\n1. have experience in working with biological fathers of children aged 2 to 12 years who have a formal diagnosis of a developmental disability, including autism spectrum disorder, attention deficit\u002Fhyperactivity disorder, intellectual disability, or related neurodevelopmental conditions,\n2. are able to speak Cantonese and read Chinese.","ALL",{"count":18,"type":19},20,"ESTIMATED","OBSERVATIONAL","The goal of this qualitative study is to develop a therapy protocol for fathers of children with special needs in Hong Kong. The therapy is called Acceptance and Commitment Therapy (ACT), which helps people cope with difficult emotions by building psychological flexibility - the ability to accept and adjust to hard situations. The main questions it aims to answer are:\n\n1. What are the experiences and needs of fathers raising children with special needs?\n2. What content and format of an ACT programme would be most helpful for these fathers?\n\nResearchers will conduct focus group interviews with two groups of participants: fathers raising children with special needs and social workers who work with these families. The interviews will take about 60 to 90 minutes each.\n\nParticipants will:\n\n1. Take part in a recorded focus group interview\n2. Share their experiences, challenges, and views on what an ACT program should include\n\nThe findings will be used to develop a protocol for an ACT programme to improve the mental health of fathers raising children with special needs.",[23,24,25,26,27],"Caregiver Mental Health","Parenting Stress","Developmental Disabilities","Special Needs Children","FATHER",[29,30,31,32,33,34],"mental health","Father","psychological flexibility","Acceptance and Commitment Therapy","Qualitative Study","Special Needs","NOT_YET_RECRUITING","2026-05-09",{"date":38,"type":39},"2026-05-18","ACTUAL",{"date":41,"type":19},"2026-05-01",{"date":43,"type":19},"2027-05-01",{"name":45,"class":46},"The Hong Kong Polytechnic University","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":67,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":87},"100633246","a-self-instructional-online-program-for-early-childhood-and-elementary-teachers-supporting-autistic-children-and-children-with-developmental-delays-100633246","NCT07524192","A Self-Instructional Online Program for Early Childhood and Elementary Teachers Supporting Autistic Children and Children With Developmental Delays","Development and Preliminary Evaluation of a Self-Instructional Online Program for Early Childhood and Elementary Teachers Supporting Autistic Children and Children With Developmental Delays","SEED","Inclusion Criteria:\n\n* Public school teachers currently employed in kindergarten or elementary schools who hold at least a Level 2 teaching certificate (or higher).\n* Teachers who understand the purpose of the study and provide informed consent to participate.\n\nExclusion Criteria:\n\n* Teachers who have majored in special education at the undergraduate or graduate level.",true,{"count":57,"type":19},70,"INTERVENTIONAL",[60],"NA","The goal of this clinical trial is to evaluate the preliminary effectiveness and acceptability of a self-instructional, web-based teacher training program designed to support the development of autistic children and children with developmental delays.\n\nThis study aims to examine whether participation in the program can improve teachers' knowledge, attitudes, and teaching self-efficacy related to inclusive education and support for autistic children and children with developmental delays.\n\nThe main questions it aims to answer are:\n\n1. Does participation in the self-instructional program improve teachers' knowledge about autism and developmental delays?\n2. Does the program improve teachers' attitudes toward inclusive education and their teaching self-efficacy? Researchers will compare teachers who participate in the self-instructional online intervention program (SEED program) with teachers who receive comparison educational materials (Kit for Kids from Organization for Autism Research) to determine whether the intervention leads to greater improvements in knowledge, attitudes, and teaching self-efficacy.\n\nParticipants will:\n\n1. Complete an online pre-intervention survey assessing background information, knowledge, attitudes toward inclusion and neurodiversity, and teaching self-efficacy.\n2. Participate in a two-week self-instructional online program or receive comparison materials, depending on group assignment\n3. Complete an online post-intervention survey evaluating the same outcomes, as well as program satisfaction and acceptability.",[63,25,64,65,66],"Autism Spectrum Disorder","Developmental Delay","Teacher Training","Inclusive Education",[63,68,69,65,70,71,72,73,74,75,76],"Developmental delay","Developmental disabilities","Inclusive education","Kindergarten Teachers","Elemantary School Teachers","General Education Teachers","Special Education Support","Web-Based Intervention","Self-Instructional Learning","RECRUITING","2026-04-06",{"date":80,"type":39},"2026-04-13",{"date":82,"type":39},"2026-02-05",{"date":84,"type":19},"2026-12-31",{"name":86,"class":46},"Boin Choi",1,{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":16,"minAge":96,"maxAge":97,"enrollmentInfo":98,"targetDuration":4,"studyType":58,"phases":100,"briefSummary":102,"conditions":103,"keywords":106,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":120,"leadSponsor":122,"locationsCount":87},"100592728","phase-4-deutetrabenazine-treatment-for-tardive-dyskinesia-in-intellectualdevelopmental-disabilities-100592728","NCT06997198","Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual\u002FDevelopmental Disabilities","Identification, Assessment, and Treatment of Tardive Dyskinesia With Deutetrabenazine in Adults With Intellectual\u002FDevelopmental Disabilities and Co-occurring Psychiatric and\u002For Behavioral Disorders","TD-AIDD","Participant Inclusion Criteria:\n\n* Diagnosis of IDD (IQ \\\u003C 70; social\u002Fadaptive dysfunction, onset \\\u003C age 22) as per DSM-5\n* Clinical diagnosis of Tardive Dyskinesia (TD) per DSM-5 for at least 3 months before study inclusion (presence of movement disorder for at least 3 months, in absence of previous formal diagnosis of TD).\n* Eligible to receive deutetrabenazine, according to current product labeling Stable doses of all psychotropic medications for minimum of three months before study inclusion\n* Willing to remain on stable doses of all psychotropics for 24 weeks of study. If female of childbearing age, practicing acceptable form of birth control throughout study duration.\n* Subject able to comply with scheduled visits and assessments\n* Consent of subject, or legally authorized representative to study protocol.\n\nCaregiver Inclusion Criteria:\n\n* Able to understand and answer questionnaires\n* Able to comply with scheduled visits\n* Ability to be primary Caregiver for 24 weeks of study\n\nParticipant Exclusion Criteria:\n\n* Previous treatment with a VMAT2 inhibitor (tetrabenazine, valbenazine, or deutetrabenazine).\n* Treatment with any investigational drug in the 30 days prior to study entry.\n* Currently taking a strong CYP2D6 inhibitor such as fluoxetine, paroxetine, quinidine, bupropion. Current treatment with strong anticholinergic agents, monoamine oxidase inhibitors, metoclopramide, dopamine agonists, L-DOPA, or stimulants within past 30 days, or botulinum toxin within the past 3 months.\n* Any unstable medical condition in the 60 days prior to study entry.\n* Pregnant or breast-feeding\n* Current or recent hepatic impairment\n* History of neuroleptic malignant syndrome\n* History of long QTc on electrocardiogram, bundle branch block (BBB), atrioventricular block, serious cardiac arrhythmia, or heart failure.\n\nQTc on EKG \\> 450 msec (Fredericia formula) on EKG within 3 months prior to study entry.\n\n* History of substance abuse or dependence in the 3 months prior to study entry.\n* Significant risk of suicide or dangerous aggression to others at time of or 3 months prior to study entry.\n* Inability to take study medications\n\nCaregiver Exclusion Criteria:\n\n* Unable to complete questionnaires\n* Unable to comply with scheduled visits\n* Will not be a primary Caregiver for the 24 weeks of the study","18 Years","89 Years",{"count":99,"type":19},25,[101],"PHASE4","The primary goal of this study is to investigate the efficacy of deutetrabenazine treatment of TD in this previously untreated patient population. Compare movement disorder deutetrabenazine treatment response in persons with IDD to response seen in patients without IDD treated with deutetrabenazine in other treatment settings (per literature review). Compare global deutetrabenazine treatment response with validated instruments.\n\nIn addition, we plan to:\n\n* Assess the safety of deutetrabenazine in the treatment of TD in persons with IDD.\n* Assess change in Activities of Daily Living (ADLs) in persons with IDD and TD treated with deutetrabenazine, utilizing a validated ADL instrument.\n* Assess change in Quality of Life (QOL) in persons with IDD and TD treated with deutetrabenazine, utilizing a validated QOL instrument.\n* Assess caregiver burden with a validated caregiver burden instrument.\n\nIn this study, 25 participants with IDD and TD will undergo Deutetrabenazine treatment for 24 weeks. The participants will be seen for a total of 5 visits: at baseline, and at follow up visits at 3 weeks, 6 weeks, 12 weeks, and 24 weeks.\n\nThis study does not include a comparison group. Therefore, researchers will compare the response of the study participants to deutetrabenazine treatment with those from a previous reported work that resulted in the FDA approval of this medication. This will be an open-label, Phase 4 study.",[104,105,25],"Tardive Dyskinesia","Intellectual Disability",[107,108,109,110,111,112,113,114,115],"movement disorders","antipsychotic medication adverse effects","Abnormal Involuntary Movement Scale","quality of life","adaptive behavior","caregiver burden","deutetrabenazine","selective vesicular monoamine transporter 2 inhibitor","VMAT2 inhibitor","2026-04-03",{"date":118,"type":39},"2026-04-09",{"date":41,"type":19},{"date":121,"type":19},"2027-10-01",{"name":123,"class":46},"University Hospitals Cleveland Medical Center",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":131,"maxAge":96,"enrollmentInfo":132,"targetDuration":134,"studyType":20,"phases":4,"briefSummary":135,"conditions":136,"keywords":145,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":87},"100567463","magnetoencephalography-in-children-100567463","NCT06668519","Magnetoencephalography in Children","An Observational Study on the Clinical Application of Magnetoencephalography in Children With Neurodevelopmental Disorders","Inclusion Criteria:\n\n1. aged 1 month-18 years old (date of investigate minus date of birth)\n2. epilepsy\n3. intracranial tumors\n4. cerebrovascular diseases\n5. autism\n6. mental retardation\n7. ADHD\n8. tic disorder\n9. neuropsychiatric disorders\n\nExclusion Criteria:\n\n1.Unable to cooperate with the exam of MEG","1 Month",{"count":133,"type":19},1500,"3 Years","This study is a single-center observational clinical study, which evaluates the diagnostic value of magnetoencephalography (MEG) in the diagnosis of neurodevelopmental diseases in children, such as the localization of epileptic foci and brain functional areas, intracranial tumors, cerebrovascular diseases, autism, mental retardation, and neuropsychiatric disorders.",[137,138,139,140,141,142,143,144,25],"Epilepsy","Intracranial Tumors","Cerebrovascular Disease","Autism","ADHD - Attention Deficit Disorder With Hyperactivity","Neuropsychiatric Disorders","Tic Disorder, Childhood","Mental Retardation",[146,147,148],"neurodevelopmental diseases","magnetoencephalography","pediatric","2026-03-24",{"date":151,"type":39},"2026-03-25",{"date":153,"type":39},"2024-09-25",{"date":155,"type":19},"2027-12-30",{"name":157,"class":46},"Children's Hospital of Fudan University",{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":165,"minAge":4,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":58,"phases":168,"briefSummary":169,"conditions":170,"keywords":171,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":4},"100628236","act-dads-power-feasibility-rct-for-fathers-of-children-with-special-needs-100628236","NCT07459010","ACT Dad's Power: Feasibility RCT for Fathers of Children With Special Needs","ACT Dad's Power: A Feasibility Randomized Controlled Trial of Acceptance and Commitment Therapy (ACT) for Fathers of Children With Special Needs in Improving Their Psychological Flexibility and Mental Health","Inclusion Criteria:\n\n* (1) who are the biological fathers of children aged 2 to 12 years\n* (2) with a child having a formal diagnosis of a developmental disability, including autism spectrum disorder, attention deficit\u002Fhyperactivity disorder, intellectual disability, or related neurodevelopmental conditions\n* (3) who are able to speak Cantonese and read Chinese\n\nExclusion Criteria:\n\n* (1) who are currently undergoing psychotherapies\n* (2) with physical or cognitive impairment and learning problems as identified from NGO or related medical records\n* (3) who exhibit a high risk of serious mental illnesses screened using the Kessler Psychological Distress Scale , with a score of ≥13","MALE",{"count":167,"type":19},50,[60],"Objective: (1) To examine the feasibility of proceeding to a future definitive RCT of ACT in Hong Kong Chinese fathers rearing children with special needs. (2) To calculate the effect sizes of the intervention on fathers' psychological flexibility, shame, guilt, and quality of life (QoL) at the 6-month follow-up. (3) To calculate the potential efficacy of the intervention.\n\nMethods: A 2-arm feasibility randomised controlled trail will be conducted on 50 fathers of children with special needs. 25 participants will be allocated into the intervention group to attend 6 weekly 45-60 minute sessions of ACT with VR. 25 participants will be allocated to the control group receiving 6 weekly 45-60 minute sessions of health talks and simple social support.\n\nOutcome and measurement: Primary outcomes are screening rate, eligibility rate, consent rate, randomization rate, attendance rate, adherence rate, retention rate, completion rate, missing data, and adverse events. Secondary outcomes are the effect sizes and preliminary efficacy of the intervention on psychological flexibility, shame, guilt, depressive symptoms, and QoL at T4. Both groups will be required to fill in a set of questionnaires at the start of intervention (T1), post-intervention (T2), 3 (T3), and 6 months (T4) after the end of intervention. They will also be invited to join semi-structure interviews at T2.\n\nData analysis: Descriptive statistics, mixed between-within-participants analysis of variance, and content analysis will be used.",[25],[29,32,30,172,173,31],"child developmental disabilities","Virtual reality","2026-03-04",{"date":176,"type":39},"2026-03-09",{"date":178,"type":19},"2026-06-01",{"date":180,"type":19},"2028-10-01",{"name":45,"class":46}]